264 related articles for article (PubMed ID: 17942922)
1. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.
Shimamura T; Royal RE; Kioi M; Nakajima A; Husain SR; Puri RK
Cancer Res; 2007 Oct; 67(20):9903-12. PubMed ID: 17942922
[TBL] [Abstract][Full Text] [Related]
2. Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine.
Fujisawa T; Nakashima H; Nakajima A; Joshi BH; Puri RK
Int J Cancer; 2011 Mar; 128(5):1221-31. PubMed ID: 20473925
[TBL] [Abstract][Full Text] [Related]
3. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
Zhang Y; Liu L; Fan P; Bauer N; Gladkich J; Ryschich E; Bazhin AV; Giese NA; Strobel O; Hackert T; Hinz U; Gross W; Fortunato F; Herr I
Oncotarget; 2015 Apr; 6(12):9999-10015. PubMed ID: 25846752
[TBL] [Abstract][Full Text] [Related]
4. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
[TBL] [Abstract][Full Text] [Related]
5. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
[TBL] [Abstract][Full Text] [Related]
6. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
7. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
[TBL] [Abstract][Full Text] [Related]
9. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.
Kang YW; Lee JE; Jung KH; Son MK; Shin SM; Kim SJ; Fang Z; Yan HH; Park JH; Han B; Cheon MJ; Woo MG; Lim JH; Kim YS; Hong SS
Cancer Lett; 2018 Dec; 438():174-186. PubMed ID: 30217561
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.
Shimamura T; Fujisawa T; Husain SR; Joshi B; Puri RK
Clin Cancer Res; 2010 Jan; 16(2):577-86. PubMed ID: 20068108
[TBL] [Abstract][Full Text] [Related]
11. Targeting interleukin-4 receptors for effective pancreatic cancer therapy.
Kawakami K; Kawakami M; Husain SR; Puri RK
Cancer Res; 2002 Jul; 62(13):3575-80. PubMed ID: 12097255
[TBL] [Abstract][Full Text] [Related]
12. The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.
Jung DB; Yun M; Kim EO; Kim J; Kim B; Jung JH; Wang E; Mukhopadhyay D; Hammond E; Dredge K; Shridhar V; Kim SH
Oncotarget; 2015 Mar; 6(7):4992-5004. PubMed ID: 25669977
[TBL] [Abstract][Full Text] [Related]
13. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
[TBL] [Abstract][Full Text] [Related]
14. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
Mol Cancer Ther; 2012 Dec; 11(12):2644-53. PubMed ID: 23047891
[TBL] [Abstract][Full Text] [Related]
15. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.
Kawakami M; Kawakami K; Stepensky VA; Maki RA; Robin H; Muller W; Husain SR; Puri RK
Clin Cancer Res; 2002 Nov; 8(11):3503-11. PubMed ID: 12429641
[TBL] [Abstract][Full Text] [Related]
17. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
[TBL] [Abstract][Full Text] [Related]
18. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine.
Wang K; Huynh N; Wang X; Baldwin G; Nikfarjam M; He H
Int J Oncol; 2018 Jan; 52(1):261-269. PubMed ID: 29115428
[TBL] [Abstract][Full Text] [Related]
20. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
